Page 25 - Genentech News Today

AML is a deadly form of blood cancer, but advancements in treatment options have improved survival rates, particularly for children.

Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) Q4 2023 Earnings Call Transcript February 28, 2024 Kiniksa Pharmaceuticals, Ltd. isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Good day and thank you for standing by. Welcome to the Kiniksa Pharmaceuticals Fourth Quarter and Full […]

Omalizumab reduced the incidence of allergic reactions to multiple food items in a double-blind trial.

Natera, Inc. (NASDAQ:NTRA) Q4 2023 Earnings Call Transcript February 28, 2024 Natera, Inc. isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Ladies and gentlemen, thank you for standing by. My name is Desiree, and I will be your conference operator […]

Nautilus Biotechnology, Inc. (NASDAQ:NAUT) Q4 2023 Earnings Call Transcript February 28, 2024 Nautilus Biotechnology, Inc. beats earnings expectations. Reported EPS is $0.14, expectations were $-0.16. NAUT isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Good day, and thank you for […]

A medication used to treat asthma can now be used to help people with food allergies avoid severe reactions.

Jazz Pharmaceuticals plc misses on earnings expectations. Reported EPS is $5.02 EPS, expectations were $5.26.

Healthcare

In an interview with me earlier this week via videoconference, Genentech’s Adam Pryor explained the company became involved with the musical because they develop a med...

Xolair receives FDA approval for severe food allergies. The researchers whose work led to the announcement claim it is a "game-changer" for allergy sufferers.